Etanercept

Generic Name: Etanercept

Brand Names: Enbrel, Eticovo, Benepali, Erelzi, Nepexto

Drug Type: Biotech

Chemical Formula: -

CAS Number: 185243-69-0

Unique Ingredient Identifier: OP401G7OJC

Background: Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technolo...

Indication: Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is al...

Associated Conditions: Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis

Associated Therapies: -

Clinical Trials

Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel

Completed

Conditions: Spondyloarthrosis

Interventions: Drug: Etanercept

First Posted Date: 2020-08-11

Last Posted Date: 2021-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 763

Registration Number: NCT04507776

Locations: 🇮🇶
Pfizer, Baghdad, Iraq

This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.

Completed

Conditions: Arthritis Rheumatoid

Interventions: Drug: Etanercept

First Posted Date: 2020-02-13

Last Posted Date: 2023-07-07

Lead Sponsor: Pfizer

Target Recruit Count: 1226

Registration Number: NCT04267614

Locations: 🇮🇶
Pfizer, Baghdad, Iraq

TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset

Phase 1

Recruiting

Conditions: Gulf War Illness

Interventions: Drug: Etanercept
Drug: Mifepristone

First Posted Date: 2020-02-05

Last Posted Date: 2024-10-14

Lead Sponsor: Nova Southeastern University

Target Recruit Count: 20

Registration Number: NCT04254627

Locations: 🇺🇸
Miami VA Healthcare System, Miami, Florida, United States
🇺🇸
Nova Southeastern University, Davie, Florida, United States

Understanding GWI: Integrative Modeling

Phase 1

Conditions: Gulf War Illness
Persian Gulf Syndrome
Occupational Diseases

Interventions: Drug: Etanercept
Drug: Mifepristone

First Posted Date: 2020-02-05

Last Posted Date: 2020-02-05

Lead Sponsor: South Florida Veterans Affairs Foundation for Research and Education

Target Recruit Count: 20

Registration Number: NCT04255498

Locations: 🇺🇸
Miami VA Healthcare System, Miami, Florida, United States

Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel

Phase 3

Conditions: Rheumatoid Arthritis

Interventions: Drug: Enbrel
Drug: Etanercept

First Posted Date: 2019-09-06

Last Posted Date: 2021-02-03

Lead Sponsor: Joint Stock Company "Farmak"

Target Recruit Count: 160

Registration Number: NCT04079374

Locations: 🇺🇦
PU Kryvyi Rih City Clinical Hospital №2 of the Dnipropetrovsk regional council, Kryvyi Rih, Dnipropetrovsk Region, Ukraine
🇺🇦
Ivano-Frankivsk Central City Clinical Hospital, Ivano-Frankivsk, Ivano-Frankivsk Region, Ukraine
🇺🇦
Khmelnytskyi Regional Hospital, Khmelnytskyi, Khmelnytskyi Region, Ukraine

and more 7 locations

A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis

Phase 2

Active, not recruiting

Conditions: Moderate-to-severe Chronic Plaque Psoriasis

Interventions: Drug: Tildrakizumab
Drug: Placebo
Drug: Etanercept

First Posted Date: 2019-06-25

Last Posted Date: 2024-06-21

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 130

Registration Number: NCT03997786

Locations: 🇺🇸
Site 2, Thousand Oaks, California, United States
🇺🇸
Site 1, Fountain Valley, California, United States
🇺🇸
Site 20, Miami, Florida, United States

and more 30 locations

Advanced Therapeutics in Rheumatoid Arthritis (RA)

Phase 4

Recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: tofacitinib
Drug: Etanercept

First Posted Date: 2019-06-05

Last Posted Date: 2024-11-28

Lead Sponsor: Lawson Health Research Institute

Target Recruit Count: 144

Registration Number: NCT03976245

Locations: 🇨🇦
Rheumatology Clinic, St. Joseph's Health Care, London, Ontario, Canada

Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC

Phase 1

Completed

Conditions: Metastatic Castration-resistant Prostate Cancer
Prostate Cancer

Interventions: Drug: acapatamab
Drug: Cytochrome P450 (CYP) Cocktail
Drug: Pembrolizumab
Drug: Etanercept

First Posted Date: 2019-01-03

Last Posted Date: 2024-12-06

Lead Sponsor: Amgen

Target Recruit Count: 212

Registration Number: NCT03792841

Locations: 🇺🇸
City of Hope at Long Beach Elm, Long Beach, California, United States
🇺🇸
El Camino Hospital, Campbell, California, United States
🇺🇸
Indiana University, Indianapolis, Indiana, United States

and more 27 locations